CSF Biomarkers

CSF Biomarkers

With an ever growing population of aged individuals who are at risk of developing Alzheimer’s disease (AD), there is an urgent need for a sensitive, specific and preferably non-invasive diagnostic standard of disease progression. Diagnosis of AD is still largely based on exclusion criteria of secondary causes and other forms of dementia with similar clinical pictures, than the diagnostic accura...

Diagnostic performance of CSF biomarkers in CJD

New CSF biomarkers on the block

A growing number of cerebrospinal fluid biomarkers are now available to capture different aspects of Alzheimer’s disease. People are increasingly aware that these biomarkers represent a real-time reflection of pathological mechanisms that are ongoing in the brain. These novel markers can be added to the panel of existing ones like amyloid beta, total Tau and phosphoTau that are currently used f...

Novel CSF biomarkers for frontotemporal lobar degenerations.

OBJECTIVE To identify antemortem CSF diagnostic biomarkers that can potentially distinguish between the 2 main causes of frontotemporal lobar degeneration (FTLD), i.e., FTLD with TDP-43 pathology (FTLD-TDP) and FTLD with tau pathology (FTLD-tau). METHODS CSF samples were collected antemortem from 23 patients with FTLD with known pathology to form a autopsy cohort as part of a comparative biom...

CSF biomarkers of AD: monitoring therapeutic targets

grounds, implying the presence of senile plaques and neurofibrillary tangles in the hippocampus and cerebral cortex. Brain autopsy studies indicate that these lesions are present in about 90% of patients clinically diagnosed by experienced physicians. The utility of biomarkers for enhancing diagnositic sensitivity for AD may consequently be relatively limited since clinical methods are generall...